AZGP1 and prostate carcinoma: Abundant evidence demonstrates that the loss of expression of AZGP1—just like Zn—in tumor cells is a negative prognostic biomarker for different solid tumors, including breast, gastric, esophageal, soft tissue and prostate cancers.